Recently identified potential therapeutic application of TP antagonists
| Antagonist | Route | Dose | Species | Experimental Model | Indication | Reference |
|---|---|---|---|---|---|---|
| GR-32191 (vapiprost) | Oral (drinking water) | 1 mg · kg−1 · day−1 | Mouse | STZ diabetes | Diabetic retinopathy | Wright et al., 2009 |
| KP-496 | Intratracheal | 30 and 100 μm/animal | Rat | Sephadex induced airway inflammation | Asthma | Ishimura et al., 2009 |
| KP-496 | Intranasal | 0.003–0.05% | Guinea pig | Ovalbumin, Japanese cedar pollen allergy | Allergic rhinitis | Mizutani et al., 2008 |
| ONO-3708 | Intradermal | 0.1 and 1 nmol/site | Mouse | TxA2-induced scratching | Pruritus | Andoh et al., 2007 |
| S18886 (terutroban) | Oral | 10 and 30 mg/kg | Rat | Uninephrectomized obese Zucker rats | Type 2 diabetes | Sebeková et al., 2007 |
STZ, streptozotocin; ONO-3708, (1S-(1α,2β(Z),3α(S*),5α))-7-(3-((cyclopentylhydroxyacetyl)amino)-6,6-dimethylbicyclo(3.1.1)hept-2-yl)-5-heptenoic acid.